Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    "Cutaneous mastocytosis"
Show Display Options
Rank Status Study
21 Recruiting A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
22 Completed Stem Cell Transplantation to Treat Systemic Mastocytosis
Condition: Mastocytosis
Intervention: Procedure: Stem cell transplantation
23 Unknown  Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Conditions: Mastocytosis, Systemic;   Leukemia, Mast-Cell
Intervention: Drug: PKC 412
24 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
25 Terminated Cromoglicate in Mastocytosis
Condition: Mastocytosis
Interventions: Drug: Cromoglicate;   Drug: Placebo
26 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
27 Recruiting Use of Tamoxifen in Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention:
28 Completed Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Condition: Mastocytosis
Intervention: Drug: masitinib (AB1010)
29 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
30 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
31 Completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Nonneoplastic Condition;   Precancerous Condition
Intervention: Drug: tanespimycin
32 Completed Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
Conditions: Atopic Dermatitis;   Healthy;   Mastocytosis
Intervention:
33 Unknown  Evaluation of Response of Dasatinib to Treat Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Dasatinib
34 Completed A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive);   Hypereosinophilic Syndrome;   Systemic Mastocytosis
Intervention: Drug: Nilotinib
35 Unknown  Imatinib in KIT-negative Systemic Mastocytosis
Condition: Systemic Mastocytosis
Intervention: Drug: Imatinib Mesylate
36 Terminated Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter
Conditions: Malignant Mast Cell Tumors;   Solid Organ Sites
Intervention: Other: QUALITY OF LIFE QUESTIONNAIRE

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Indicates status has not been verified in more than two years